Clinical Trial Science: Semaglutide & Tirzepatide
An evidence-based analysis of GLP-1 hormone receptors, metabolic efficacy parameters, and peer-reviewed study conclusions.
Weight Reduction Percentage Over Time (Weeks)
Visualizing average body weight reduction results from standard clinical study protocols.
1. Semaglutide: STEP Clinical Trial Overview
Semaglutide acts as a selective GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the natural GLP-1 hormone, which is released by the intestines in response to food intake, signaling to the brain that you are full and slowing stomach emptying.
In the landmark **STEP-1 Clinical Trial** (Semaglutide Treatment Effect in People with Obesity), published in the New England Journal of Medicine (NEJM), investigators evaluated 1,961 adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related coexisting condition).
- Mean Weight Loss: Participants on Semaglutide lost an average of **14.9%** of their initial body weight, compared to only **2.4%** in the placebo group over 68 weeks.
- Response Rate: **86.4%** of participants on Semaglutide achieved a weight reduction of 5% or more.
- Cardiometabolic Improvements: Clinically significant reductions in waist circumference, blood pressure, fasting lipids, and inflammatory markers were observed.
2. Tirzepatide: SURMOUNT & SURPASS Clinical Trial Overview
Tirzepatide is a novel therapeutic agent representing a dual-receptor model. It targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. By acting on both pathways, Tirzepatide provides enhanced appetite suppression and metabolic control compared to single GLP-1 agonists.
In the **SURMOUNT-1 Clinical Trial**, published in PubMed/NCBI, researchers evaluated the efficacy and safety of Tirzepatide in 2,539 adults with obesity.
- Mean Weight Loss: At the highest dosage level (15 mg), participants achieved an average weight reduction of **20.9%** over 72 weeks.
- Response Rate: An impressive **90.9%** of participants on the 15 mg dose achieved 5% or more weight loss.
- Impact on Glycemic Control: Significantly improved insulin sensitivity and HbA1c values.
Scientific References & Citations
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. Link to NEJM Publication
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022. Link to PubMed Publication
- FDA Approves Wegovy (Semaglutide) Injection for Chronic Weight Management. FDA Official Announcement
Ready to Start Your Program?
Complete your medical intake questionnaire. A licensed practitioner will review your profile to check eligibility for Semaglutide or Tirzepatide.
Start Intake Questionnaire